<div id="readability-page-1"><p>Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s stock price shot up 5.8% during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $1.74 and last traded at $1.7350. Approximately 1,928,143 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 2,946,142 shares. The stock had previously closed at $1.64.</p><p>The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The company had revenue of $5.49 million during the quarter, compared to analysts' expectations of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. </p><h2>Key Headlines Impacting Lexicon Pharmaceuticals</h2><p>Here are the key news stories impacting Lexicon Pharmaceuticals this week:</p><ul>   <li><span>Positive Sentiment: </span>Q4 results beat expectations: GAAP EPS of -$0.04 vs. consensus -$0.07 and revenue of $5.49M vs. $3.14M — the upside to both EPS and revenue supports near-term optimism. <i></i><span>Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M</span></li>    <li><span>Positive Sentiment: </span>Clinical and corporate progress: management said pivotal sotagliflozin milestones remain on schedule (NDA resubmission in T1D, SONATA enrollment for HCM) and pilavapadin received a positive End-of-Phase 2 FDA meeting supporting Phase 3 readiness — these de-risk upcoming catalysts. The company also reported &gt;$100M of additional cash from a capital raise and a Novo Nordisk milestone, strengthening the balance sheet. <i></i><span>Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates</span></li>    <li><span>Positive Sentiment: </span>Analyst upgrade / price-target lift: HC Wainwright reiterated a Buy and raised its PT from $4 to $6, implying substantial upside from current levels — analyst support can attract buying interest. <i></i><span>Benzinga coverage of HC Wainwright PT raise</span></li>    <li><span>Neutral Sentiment: </span>Conference materials and call transcripts available: the company filed a press release, slide deck and held a conference call (transcripts available) — useful for digging into guidance, cash runway and trial timelines but not a direct price driver by itself. <i></i><span>View Press Release / Slide Deck</span></li>    <li><span>Neutral Sentiment: </span>Multiple outlets published earnings call transcripts and snapshots (Seeking Alpha, InsiderMonkey, Yahoo, WTOP) — increases transparency and coverage but mainly reiterates the same beats and updates. <i></i><span>InsiderMonkey earnings call transcript</span></li>    <li><span>Negative Sentiment: </span>Company remains unprofitable with negative ROE and net margin; consensus still expects a full-year EPS loss (current consensus ~ -$0.66). Continued clinical and regulatory risk plus negative earnings projections mean upside depends on successful trial and regulatory outcomes. <i></i><span>MarketBeat company profile and consensus estimates</span></li> </ul><h2>Analysts Set New Price Targets</h2><p>Several research analysts have commented on LXRX shares. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Finally, HC Wainwright upped their price objective on Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday. Three research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $4.63.</p><p><b>Get Our Latest Research Report on Lexicon Pharmaceuticals</b></p><h2>Insider Activity</h2><p>In related news, Director Raymond Debbane acquired 100,000 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director directly owned 1,904,186 shares of the company's stock, valued at approximately $2,799,153.42. The trade was a 5.54% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Invus Global Management, Llc bought 1,538,462 shares of the company's stock in a transaction that occurred on Monday, February 2nd. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares of the company's stock, valued at $2,000,000.60. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 1,790,462 shares of company stock worth $2,369,981. 13.90% of the stock is currently owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. UBS Group AG lifted its stake in shares of  Lexicon Pharmaceuticals by 752.1% in the 4th quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company's stock valued at $3,458,000 after purchasing an additional 2,654,315 shares during the last quarter.  CIBC Bancorp USA Inc. bought a new stake in  Lexicon Pharmaceuticals during the third quarter worth approximately $3,240,000.  Millennium Management LLC grew its holdings in  Lexicon Pharmaceuticals by 133.1% during the third quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company's stock valued at $5,171,000 after purchasing an additional 2,187,396 shares during the last quarter.  Marshall Wace LLP acquired a new position in  Lexicon Pharmaceuticals during the fourth quarter valued at approximately $1,452,000.  Finally, AQR Capital Management LLC acquired a new stake in shares of  Lexicon Pharmaceuticals in the first quarter worth $541,000. 74.70% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Lexicon Pharmaceuticals Price Performance</h2><p>The stock has a market cap of $623.35 million, a price-to-earnings ratio of -9.03 and a beta of 0.94. The stock has a fifty day simple moving average of $1.35 and a 200-day simple moving average of $1.33. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. </p><h2>About Lexicon Pharmaceuticals</h2> (Get Free Report)<p>Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.  </p><p>The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Lexicon Pharmaceuticals</li><li>BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align</li><li>J.P. Morgan is betting on this coin</li><li>Your name isn't on our protected list yet</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Lexicon Pharmaceuticals Right Now?</h2><p>Before you consider Lexicon Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.</p><p>While Lexicon Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Lexicon Pharmaceuticals (NASDAQ:LXRX) shares rose 5.8% after the company reported better-than-expected quarterly earnings, with EPS of -$0.04 beating estimates of -$0.07 and revenue of $5.49 million surpassing expectations of $3.14 million. Despite a negative net margin and return on equity, analysts remain optimistic, with HC Wainwright raising its price target from $4 to $6. Insider buying activity also increased, with significant purchases made by directors. However, the company still faces profitability challenges and clinical risks.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

VG Health

VanEck Biotech ETF

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

Lexicon Pharma

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat